$ADMA
ADMA Biologics Inc

2024 Q1 Form 10-K Financial Statement

#000114036124010147 Filed on February 28, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $81.88M $73.90M $258.2M
YoY Change 43.86% 47.86% 67.59%
Cost Of Revenue $42.77M $42.82M $169.3M
YoY Change 5.86% 19.59% 42.47%
Gross Profit $39.11M $31.09M $88.94M
YoY Change 136.83% 119.27% 152.21%
Gross Profit Margin 47.77% 42.06% 34.44%
Selling, General & Admin $15.64M $16.22M $59.02M
YoY Change 7.77% -14.55% 12.51%
% of Gross Profit 39.99% 52.18% 66.36%
Research & Development $450.0K $445.5K $3.300M
YoY Change -47.39% -58.53% -8.68%
% of Gross Profit 1.15% 1.43% 3.71%
Depreciation & Amortization $1.900M $2.109M $7.600M
YoY Change 0.0% 8.88% 18.75%
% of Gross Profit 4.86% 6.78% 8.54%
Operating Expenses $17.29M $16.85M $67.31M
YoY Change -0.23% -16.72% -9.81%
Operating Profit $21.82M $14.23M $21.63M
YoY Change -2782.96% -334.93% -154.95%
Interest Expense $3.769M -$5.602M $25.03M
YoY Change -38.37% -2.31% 29.81%
% of Operating Profit 17.27% -39.36% 115.69%
Other Income/Expense, Net -$3.420M -$101.4K -$49.87M
YoY Change -42.77% -76.88% 87.92%
Pretax Income $18.40M -$17.64M -$28.24M
YoY Change -371.05% 44.25% -57.15%
Income Tax $600.0K $0.00
% Of Pretax Income 3.26%
Net Earnings $17.81M -$17.64M -$28.24M
YoY Change -362.28% 44.25% -57.15%
Net Earnings / Revenue 21.75% -23.88% -10.94%
Basic Earnings Per Share $0.08 -$0.13
Diluted Earnings Per Share $0.08 -$0.08 -$0.13
COMMON SHARES
Basic Shares Outstanding 228.2M 226.0M 224.0M
Diluted Shares Outstanding 236.4M 224.0M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $45.33M $51.35M $51.35M
YoY Change -34.51% -40.65% -40.65%
Cash & Equivalents $45.33M $51.35M $51.35M
Short-Term Investments
Other Short-Term Assets $3.741M $5.334M $5.334M
YoY Change -14.56% 4.69% 4.69%
Inventory $177.7M $172.9M $172.9M
Prepaid Expenses
Receivables $49.60M $27.40M $27.42M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $276.4M $257.0M $257.0M
YoY Change 4.67% -4.95% -4.95%
LONG-TERM ASSETS
Property, Plant & Equipment $55.32M $53.84M $63.47M
YoY Change -3.58% -7.6% -7.68%
Goodwill $3.500M $3.500M
YoY Change -0.84% 0.0%
Intangibles $321.0K $499.0K
YoY Change -61.54% -50.76%
Long-Term Investments
YoY Change
Other Assets $5.891M $4.670M $4.670M
YoY Change 24.84% -2.1% -2.1%
Total Long-Term Assets $74.46M $72.17M $72.17M
YoY Change -2.93% -7.55% -7.55%
TOTAL ASSETS
Total Short-Term Assets $276.4M $257.0M $257.0M
Total Long-Term Assets $74.46M $72.17M $72.17M
Total Assets $350.9M $329.2M $329.2M
YoY Change 2.96% -5.53% -5.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $17.19M $15.66M $15.66M
YoY Change 32.64% 18.37% 18.37%
Accrued Expenses $32.40M $31.05M $31.05M
YoY Change 50.11% 28.86% 28.86%
Deferred Revenue $1.118M $182.0K
YoY Change 682.73% 27.42%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $53.10M $49.80M $49.81M
YoY Change 44.58% 26.82% 26.84%
LONG-TERM LIABILITIES
Long-Term Debt $130.8M $130.6M $130.6M
YoY Change -9.32% -8.57% -8.57%
Other Long-Term Liabilities $405.0K $419.0K $13.58M
YoY Change 19.56% 19.56% -5.64%
Total Long-Term Liabilities $405.0K $419.0K $144.2M
YoY Change 19.56% 19.56% -8.3%
TOTAL LIABILITIES
Total Short-Term Liabilities $53.10M $49.80M $49.81M
Total Long-Term Liabilities $405.0K $419.0K $144.2M
Total Liabilities $197.2M $194.0M $194.0M
YoY Change 1.04% -1.28% -1.28%
SHAREHOLDERS EQUITY
Retained Earnings -$488.5M -$506.3M
YoY Change 0.75% 5.91%
Common Stock $23.00K $23.00K
YoY Change 3.48% 3.69%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $153.7M $135.2M $135.2M
YoY Change
Total Liabilities & Shareholders Equity $350.9M $329.2M $329.2M
YoY Change 2.96% -5.53% -5.53%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income $17.81M -$17.64M -$28.24M
YoY Change -362.28% 44.25% -57.15%
Depreciation, Depletion And Amortization $1.900M $2.109M $7.600M
YoY Change 0.0% 8.88% 18.75%
Cash From Operating Activities -$2.218M $17.60M $8.800M
YoY Change -84.93% -338.45% -114.79%
INVESTING ACTIVITIES
Capital Expenditures $2.347M $1.407M $4.771M
YoY Change 20.69% -62.46% -65.7%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$2.362M -$1.407M -$4.981M
YoY Change 21.46% -62.46% -64.19%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.447M -38.99M -38.99M
YoY Change 122.44% -162.15% -135.82%
NET CHANGE
Cash From Operating Activities -2.218M 17.60M 8.800M
Cash From Investing Activities -2.362M -1.407M -4.981M
Cash From Financing Activities -1.447M -38.99M -38.99M
Net Change In Cash -6.027M -22.81M -35.17M
YoY Change -65.2% -144.18% -199.26%
FREE CASH FLOW
Cash From Operating Activities -$2.218M $17.60M $8.800M
Capital Expenditures $2.347M $1.407M $4.771M
Free Cash Flow -$4.565M $16.19M $4.029M
YoY Change -72.61% -245.48% -105.49%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<div><span style="text-decoration: underline;"></span></div> <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 9pt; text-indent: -9pt; text-align: left;"><span style="text-decoration: underline;">Use of estimates</span></p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 9pt; text-indent: -9pt; text-align: left;"> <br/> </p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include rebates and chargebacks deducted from gross revenues, valuation of inventory, assumptions used in projecting future liquidity and capital requirements, assumptions used in the fair value of awards granted under the Company’s equity incentive plans and warrants issued in connection with the issuance of notes payable and the valuation allowance for the Company’s deferred tax assets.</p>
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001368514
CY2023 dei Auditor Firm
AuditorFirmId
596
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-36728
CY2023 dei Entity Registrant Name
EntityRegistrantName
ADMA BIOLOGICS, INC.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
56-2590442
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
465 State Route 17
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Ramsey
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07446
CY2023 dei City Area Code
CityAreaCode
201
CY2023 dei Local Phone Number
LocalPhoneNumber
478-5552
CY2023 dei Security12b Title
Security12bTitle
Common stock, par value $0.0001 per share
CY2023 dei Trading Symbol
TradingSymbol
ADMA
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
793963197
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
228220236
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023 dei Auditor Name
AuditorName
CohnReznick LLP
CY2023 dei Auditor Location
AuditorLocation
Parsippany, New Jersey
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51352000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
86522000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
27421000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
15505000
CY2023Q4 us-gaap Inventory Net
InventoryNet
172906000
CY2022Q4 us-gaap Inventory Net
InventoryNet
163280000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5334000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5095000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
257013000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
270402000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
53835000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
58261000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
499000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1013000
CY2023Q4 us-gaap Goodwill
Goodwill
3530000
CY2022Q4 us-gaap Goodwill
Goodwill
3530000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9635000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10485000
CY2023Q4 adma Deposits And Other Noncurrent Assets
DepositsAndOtherNoncurrentAssets
4670000
CY2022Q4 adma Deposits And Other Noncurrent Assets
DepositsAndOtherNoncurrentAssets
4770000
CY2023Q4 us-gaap Assets
Assets
329182000
CY2022Q4 us-gaap Assets
Assets
348461000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
15660000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
13229000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
32919000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
24990000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
182000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
143000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1045000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
905000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
49806000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
39267000
CY2023Q4 us-gaap Senior Long Term Notes
SeniorLongTermNotes
130594000
CY2022Q4 us-gaap Senior Long Term Notes
SeniorLongTermNotes
142833000
CY2023Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1690000
CY2022Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1833000
CY2023Q4 adma Long Term Liability End Of Term Fee Payable
LongTermLiabilityEndOfTermFeePayable
1688000
CY2022Q4 adma Long Term Liability End Of Term Fee Payable
LongTermLiabilityEndOfTermFeePayable
1500000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9779000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10704000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
419000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
350000
CY2023Q4 us-gaap Liabilities
Liabilities
193976000
CY2022Q4 us-gaap Liabilities
Liabilities
196487000
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
226063032
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
226063032
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
221816930
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
221816930
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
23000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
22000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
641439000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
629969000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-506256000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-478017000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
135206000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
151974000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
329182000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
348461000
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
258215000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
154080000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
80943000
CY2023 us-gaap Cost Of Revenue
CostOfRevenue
169273000
CY2022 us-gaap Cost Of Revenue
CostOfRevenue
118815000
CY2021 us-gaap Cost Of Revenue
CostOfRevenue
79770000
CY2023 us-gaap Gross Profit
GrossProfit
88942000
CY2022 us-gaap Gross Profit
GrossProfit
35265000
CY2021 us-gaap Gross Profit
GrossProfit
1173000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3300000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3614000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3646000
CY2023 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
4266000
CY2022 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
17843000
CY2021 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
12289000
CY2023 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
724000
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
715000
CY2021 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
715000
CY2023 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
59020000
CY2022 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
52458000
CY2021 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
42897000
CY2023 us-gaap Operating Expenses
OperatingExpenses
67310000
CY2022 us-gaap Operating Expenses
OperatingExpenses
74630000
CY2021 us-gaap Operating Expenses
OperatingExpenses
59547000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
21632000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-39365000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-58374000
CY2023 us-gaap Investment Income Interest
InvestmentIncomeInterest
1617000
CY2022 us-gaap Investment Income Interest
InvestmentIncomeInterest
45000
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
35000
CY2023 us-gaap Interest Expense
InterestExpense
25027000
CY2022 us-gaap Interest Expense
InterestExpense
19279000
CY2021 us-gaap Interest Expense
InterestExpense
13057000
CY2023 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-26174000
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-6670000
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-287000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-635000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-252000
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-49871000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-26539000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-13274000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-28239000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-65904000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-71648000
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.33
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.33
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.51
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
223977315
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
223977315
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
197874895
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
197874895
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
139578538
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
139578538
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
88249000
CY2021 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3488000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
121144000
CY2021 adma Vesting Of Restricted Stock Units Net Of Shares Withheld For Taxes And Retired Amount
VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount
-60000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-71648000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
141173000
CY2022 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
5215000
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
64644000
CY2022 adma Vesting Of Restricted Stock Units Net Of Shares Withheld For Taxes And Retired Amount
VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount
-2899000
CY2022 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
9570000
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
175000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-65904000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
151974000
CY2023 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
6187000
CY2023 adma Vesting Of Restricted Stock Units Net Of Shares Withheld For Taxes And Retired Amount
VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount
-1415000
CY2023 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
5595000
CY2023 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1104000
CY2023 adma Stock Issued During Period Value Cashless Exercise Of Warrants
StockIssuedDuringPeriodValueCashlessExerciseOfWarrants
0
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-28239000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
135206000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-28239000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-65904000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-71648000
CY2023 us-gaap Depreciation And Amortization
DepreciationAndAmortization
8332000
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
7113000
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
5496000
CY2023 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-182000
CY2022 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-427000
CY2021 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-221000
CY2023 us-gaap Paid In Kind Interest
PaidInKindInterest
3836000
CY2022 us-gaap Paid In Kind Interest
PaidInKindInterest
2998000
CY2021 us-gaap Paid In Kind Interest
PaidInKindInterest
0
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
6187000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
5215000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
3488000
CY2023 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
2594000
CY2022 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
2402000
CY2021 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1897000
CY2023 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-26174000
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-6670000
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2023 adma Amortization Of License Revenue
AmortizationOfLicenseRevenue
-143000
CY2022 adma Amortization Of License Revenue
AmortizationOfLicenseRevenue
-143000
CY2021 adma Amortization Of License Revenue
AmortizationOfLicenseRevenue
-143000
CY2023 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
11916000
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-13072000
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
15340000
CY2023 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
9626000
CY2022 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
38556000
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
43188000
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
239000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
756000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1293000
CY2023 adma Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
-1080000
CY2022 adma Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
-122000
CY2021 adma Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
1775000
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3839000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
800000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1356000
CY2023 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
7530000
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
7534000
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
8341000
CY2023 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-791000
CY2022 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-502000
CY2021 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
219000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
8800000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-59508000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-112369000
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4771000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13911000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13511000
CY2023 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
210000
CY2022 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0
CY2021 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4981000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-13911000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-13511000
CY2023 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
158584000
CY2022 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
100000000
CY2021 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
64645000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
121144000
CY2023 adma Payment Of Debt Refinancing Fees
PaymentOfDebtRefinancingFees
11140000
CY2022 adma Payment Of Debt Refinancing Fees
PaymentOfDebtRefinancingFees
2000000
CY2021 adma Payment Of Debt Refinancing Fees
PaymentOfDebtRefinancingFees
0
CY2023 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
135000000
CY2022 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
151750000
CY2021 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0
CY2023 adma Taxes Paid On Vested Restricted Stock Units
TaxesPaidOnVestedRestrictedStockUnits
1415000
CY2022 adma Taxes Paid On Vested Restricted Stock Units
TaxesPaidOnVestedRestrictedStockUnits
2899000
CY2021 adma Taxes Paid On Vested Restricted Stock Units
TaxesPaidOnVestedRestrictedStockUnits
62000
CY2023 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
17000
CY2022 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
36000
CY2021 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
34000
CY2023 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1104000
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
175000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2023 adma Payment Of End Of Term Fee
PaymentOfEndOfTermFee
1586000
CY2022 adma Payment Of End Of Term Fee
PaymentOfEndOfTermFee
0
CY2021 adma Payment Of End Of Term Fee
PaymentOfEndOfTermFee
0
CY2023 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
2351000
CY2022 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
2783000
CY2021 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-38989000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
108852000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
121048000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-35170000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
35433000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4832000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
86522000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51089000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
55921000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51352000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
86522000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51089000
CY2023 adma Number Of Fda Licensed Plasma Collection Facilities
NumberOfFDALicensedPlasmaCollectionFacilities
10
CY2023 adma Number Of Fda Approved Product
NumberOfFDAApprovedProduct
3
CY2023Q4 adma Working Capital
WorkingCapital
207200000
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
51400000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
27400000
CY2023Q4 us-gaap Inventory Net
InventoryNet
172900000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
49800000
CY2023Q4 adma Accounts Receivable Allowance For Contractual Credits And Doubtful Accounts
AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts
100000
CY2022Q4 adma Accounts Receivable Allowance For Contractual Credits And Doubtful Accounts
AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts
100000
CY2022Q4 us-gaap Goodwill
Goodwill
3500000
CY2023Q4 us-gaap Goodwill
Goodwill
3500000
CY2022 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2021 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2023 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2021 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2023 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2022 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2023 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
3300000
CY2022 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
2200000
CY2021 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
1400000
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23066387
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
24648346
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16876015
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
52999000
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
48644000
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
49621000
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
56171000
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
70286000
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
58465000
CY2023Q4 us-gaap Inventory Net
InventoryNet
172906000
CY2022Q4 us-gaap Inventory Net
InventoryNet
163280000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
80572000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
77738000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
26737000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
19477000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
53835000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
58261000
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
7600000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6400000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4800000
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
5217000
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
4718000
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
499000
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
5007000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
3994000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1013000
CY2021 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
700000
CY2023 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
700000
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
700000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Rolling Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths
351000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Rolling Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo
52000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Rolling Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree
52000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Rolling Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour
44000
CY2023Q4 adma Accrued Rebates Current
AccruedRebatesCurrent
16608000
CY2022Q4 adma Accrued Rebates Current
AccruedRebatesCurrent
11437000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
5954000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3167000
CY2023Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
4961000
CY2022Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
4194000
CY2023Q4 adma Accrued Testing Current
AccruedTestingCurrent
282000
CY2022Q4 adma Accrued Testing Current
AccruedTestingCurrent
310000
CY2023Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
2203000
CY2022Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
4086000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2911000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1796000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
32919000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
24990000
CY2023Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
4406000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
11915000
CY2023Q4 us-gaap Senior Long Term Notes
SeniorLongTermNotes
130594000
CY2022Q4 us-gaap Senior Long Term Notes
SeniorLongTermNotes
142833000
CY2023Q4 adma Senior Notes Payable Before Debt Discount
SeniorNotesPayableBeforeDebtDiscount
135000000
CY2022Q4 us-gaap Preferred Stock Capital Shares Reserved For Future Issuance
PreferredStockCapitalSharesReservedForFutureIssuance
10000000
CY2023Q4 us-gaap Preferred Stock Capital Shares Reserved For Future Issuance
PreferredStockCapitalSharesReservedForFutureIssuance
10000000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
226063032
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
221816930
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
31033333
CY2021Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
57500000
CY2021Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
57500000
CY2021Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
53800000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1194032
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1895550
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y7M6D
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y7M6D
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y2M12D
CY2023Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
5906184
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y7M6D
CY2023Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
3.38
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
8914000
CY2023Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
3410131
CY2023 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
P5Y2M12D
CY2023Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
3.79
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
4664000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
6187000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
5215000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
3488000
CY2023Q2 adma Number Of Batches In Production At The Time Of Disruption
NumberOfBatchesInProductionAtTheTimeOfDisruption
2
CY2023Q2 adma Number Of Batches In Production At The Time Of Disruption
NumberOfBatchesInProductionAtTheTimeOfDisruption
2
CY2023Q2 us-gaap Inventory Write Down
InventoryWriteDown
2100000
CY2023Q2 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
700000
CY2023 adma Plasma Supply Agreement Term
PlasmaSupplyAgreementTerm
P10Y
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1500000
CY2023 adma Number Of Tranches
NumberOfTranches
2
CY2023 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-5930000
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-13840000
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-15046000
CY2023 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-763000
CY2022 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-1773000
CY2021 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-252000
CY2023 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
4696000
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
15117000
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
14619000
CY2023 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
0
CY2022 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
211000
CY2021 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
240000
CY2023 adma Effective Income Tax Rate Reconciliation Change In Federal Net Operating Loss Amount
EffectiveIncomeTaxRateReconciliationChangeInFederalNetOperatingLossAmount
0
CY2022 adma Effective Income Tax Rate Reconciliation Change In Federal Net Operating Loss Amount
EffectiveIncomeTaxRateReconciliationChangeInFederalNetOperatingLossAmount
0
CY2021 adma Effective Income Tax Rate Reconciliation Change In Federal Net Operating Loss Amount
EffectiveIncomeTaxRateReconciliationChangeInFederalNetOperatingLossAmount
624000
CY2023 adma Effective Income Tax Rate Reconciliation Section162 M Disallowance
EffectiveIncomeTaxRateReconciliationSection162MDisallowance
1183000
CY2022 adma Effective Income Tax Rate Reconciliation Section162 M Disallowance
EffectiveIncomeTaxRateReconciliationSection162MDisallowance
862000
CY2021 adma Effective Income Tax Rate Reconciliation Section162 M Disallowance
EffectiveIncomeTaxRateReconciliationSection162MDisallowance
64000
CY2023 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
814000
CY2022 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-155000
CY2021 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
231000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
77757000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
81526000
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
140000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
407000
CY2023Q4 us-gaap Deferred Tax Asset Interest Carryforward
DeferredTaxAssetInterestCarryforward
21165000
CY2022Q4 us-gaap Deferred Tax Asset Interest Carryforward
DeferredTaxAssetInterestCarryforward
12194000
CY2023Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
778000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
882000
CY2023Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
434000
CY2022Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
480000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
1148000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
1236000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
101422000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
96725000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
101422000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
96725000
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023 adma Operating Lease Incremental Borrowing Rate Percent
OperatingLeaseIncrementalBorrowingRatePercent
0.13
CY2022 adma Operating Lease Incremental Borrowing Rate Percent
OperatingLeaseIncrementalBorrowingRatePercent
0.16
CY2023 us-gaap Operating Lease Expense
OperatingLeaseExpense
2400000
CY2022 us-gaap Operating Lease Expense
OperatingLeaseExpense
2100000
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
1400000
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
2400000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
1800000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
1400000
CY2023 adma Number Of New Property Leases
NumberOfNewPropertyLeases
1
CY2023Q4 adma Lessee Operating Lease Right Of Use Asset Related To Property Lease
LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease
100000
CY2023Q4 adma Lessee Operating Lease Liabilities Related To Property Lease
LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease
100000
CY2022Q4 adma Lessee Operating Lease Liabilities Related To Property Lease
LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease
4000000
CY2022Q4 adma Lessee Operating Lease Right Of Use Asset Related To Property Lease
LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease
4000000
CY2022 adma Number Of New Property Leases
NumberOfNewPropertyLeases
2
CY2023Q4 adma Operating And Financing Lease Liability
OperatingAndFinancingLeaseLiability
10800000
CY2022Q4 adma Operating And Financing Lease Liability
OperatingAndFinancingLeaseLiability
11600000
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y7M6D
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2397000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2420000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2157000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2041000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
2088000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
6151000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
17254000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
6430000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1045000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9779000
CY2023 adma Number Of Plasma Collection Facilities Under Development
NumberOfPlasmaCollectionFacilitiesUnderDevelopment
10
CY2023 adma Number Of Fda Licensed Plasma Collection Facilities Received Approval
NumberOfFDALicensedPlasmaCollectionFacilitiesReceivedApproval
3
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
258215000
CY2023 us-gaap Cost Of Revenue
CostOfRevenue
169273000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
21632000
CY2023 adma Interest And Other Nonoperating Income Expense
InterestAndOtherNonoperatingIncomeExpense
-23697000
CY2023 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-26174000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-28239000
CY2023 us-gaap Segment Expenditure Addition To Long Lived Assets
SegmentExpenditureAdditionToLongLivedAssets
4771000
CY2023 us-gaap Depreciation And Amortization
DepreciationAndAmortization
8332000
CY2023Q4 us-gaap Assets
Assets
329182000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
154080000
CY2022 us-gaap Cost Of Revenue
CostOfRevenue
118815000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-39365000
CY2022 adma Interest And Other Nonoperating Income Expense
InterestAndOtherNonoperatingIncomeExpense
-19869000
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-6670000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-65904000
CY2022 us-gaap Segment Expenditure Addition To Long Lived Assets
SegmentExpenditureAdditionToLongLivedAssets
13911000
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
7113000
CY2022Q4 us-gaap Assets
Assets
348461000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
80943000
CY2021 us-gaap Cost Of Revenue
CostOfRevenue
79770000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-58374000
CY2021 adma Interest And Other Nonoperating Income Expense
InterestAndOtherNonoperatingIncomeExpense
-13274000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-71648000
CY2021 us-gaap Segment Expenditure Addition To Long Lived Assets
SegmentExpenditureAdditionToLongLivedAssets
13511000
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
5496000
CY2021Q4 us-gaap Assets
Assets
276253000
CY2023 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
1300000
CY2022 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
1300000
CY2021 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
1100000
CY2023 us-gaap Interest Paid Net
InterestPaidNet
18051000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
13880000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
11159000
CY2023 adma Equipment Acquired Reflected In Accounts Payable And Accrued Liabilities
EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities
86000
CY2022 adma Equipment Acquired Reflected In Accounts Payable And Accrued Liabilities
EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities
1495000
CY2021 adma Equipment Acquired Reflected In Accounts Payable And Accrued Liabilities
EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities
1353000
CY2023 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
130000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4048000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3554000
CY2023 adma Warrants Issued In Connection With Notes Payable
WarrantsIssuedInConnectionWithNotesPayable
5595000
CY2022 adma Warrants Issued In Connection With Notes Payable
WarrantsIssuedInConnectionWithNotesPayable
9570000
CY2021 adma Warrants Issued In Connection With Notes Payable
WarrantsIssuedInConnectionWithNotesPayable
0
CY2023 adma Plasma Purchased
PlasmaPurchased
9500000
CY2022 adma Plasma Purchased
PlasmaPurchased
47700000
CY2023 adma Percentage Of Inventory Purchases
PercentageOfInventoryPurchases
0.21
CY2022 adma Percentage Of Inventory Purchases
PercentageOfInventoryPurchases
0.65
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
258215000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
154080000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
80943000

Files In Submission

Name View Source Status
0001140361-24-010147-index-headers.html Edgar Link pending
0001140361-24-010147-index.html Edgar Link pending
0001140361-24-010147.txt Edgar Link pending
0001140361-24-010147-xbrl.zip Edgar Link pending
adma-20231231.xsd Edgar Link pending
ef20015264_10k.htm Edgar Link pending
ef20015264_ex21-1.htm Edgar Link pending
ef20015264_ex23-1.htm Edgar Link pending
ef20015264_ex31-1.htm Edgar Link pending
ef20015264_ex31-2.htm Edgar Link pending
ef20015264_ex32-1.htm Edgar Link pending
ef20015264_ex32-2.htm Edgar Link pending
ef20015264_ex97.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image00001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ef20015264_10k_htm.xml Edgar Link completed
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
adma-20231231_def.xml Edgar Link unprocessable
adma-20231231_lab.xml Edgar Link unprocessable
adma-20231231_cal.xml Edgar Link unprocessable
adma-20231231_pre.xml Edgar Link unprocessable